clement, Author at BaseLaunch

Features

Novartis receives U.S. approval for migraine medication

Basel-based pharmaceutical company Novartis has received approval in the USA for its Aimovig migraine medication, developed with its partner, Amgen. It is a new therapeutic…

clement22.05.2018

Features

Basel, a hotspot for biotech and pharma according to Labiotech.eu

Basel is among the European biotech hubs with the most exciting companies as named by labiotech.eu. The industry platform highlighted businesses including Actelion, CRISPR Therapeutics…

clement18.05.2018

Interviews

Biotech and Why Pharma Should Be Very Afraid

Xconomy National — Arch Venture Partners co-founder and managing director Bob Nelsen is widely regarded as one of the most astute and successful life science investors and…

clement15.05.2018

Portfolio news

BaseLaunch accelerated Polyneuron raises new financing

Polyneuron Pharmaceuticals, a BaseLaunch participant, has successfully raised over 3 million Swiss francs in a financing round. The Basel-based pharmaceutical company is developing an active…

clement14.05.2018

Features

Biotech industry continues to grow

The Swiss biotech industry continued to grow in 2017. Reaching record figures in sales and capital investments in companies, according to a new report. New…

clement14.05.2018

Features

Another Trophy Quarter For VC-Backed Biotech Funding

clement30.04.2018

715px-PARP1_binding_olaparib_5DS3 targeted protein degradation

Features

Another player emerges in the targeted protein degradation field

Targeted protein degradation is really taking off. Besides Arvinas, C4 Therapeutics, and Kymera, Cedilla Therapeutics, founded by Thirdrock Ventures, has emerged with a $56 million…

clement26.04.2018

Features

IP protection is crucial for business and research

The patent law and attorney-at-law firm Vossius & Partner has been an important partner for BaseLaunch since the inception of the healthcare accelerator in 2016.…

clement24.04.2018

Features

Little by Little: Real Life Lessons In Business Development

This blog was written by Tariq Kassum, COO and Head of Corporate Development at Obsidian Therapeutics, as part of the From The Trenches feature of…

clement17.04.2018

Features

Roivant launches new subsidiary in Basel

Our healthcare partner Roivant Sciences, a pharmaceutical company based in Basel, is launching Genevant with the Canadian Arbutus Biopharma Corporation. The aim of the new…

clement12.04.2018

clement

Novartis receives U.S. approval for migraine medication

Basel, a hotspot for biotech and pharma according to Labiotech.eu

Biotech and Why Pharma Should Be Very Afraid

BaseLaunch accelerated Polyneuron raises new financing

Biotech industry continues to grow

Another Trophy Quarter For VC-Backed Biotech Funding

Another player emerges in the targeted protein degradation field

IP protection is crucial for business and research

Little by Little: Real Life Lessons In Business Development

Roivant launches new subsidiary in Basel

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us